Katharina Ribbeck

During her Ph.D. work, Ribbeck investigated the selective transport of molecules through the nuclear pore complex,[12][13] which is partly mediated by a hydrogel barrier. With her Ph.D. advisor, Dirk Görlich, Ribbeck developed a selective phase model for molecular transport through the nuclear pore barrier.[14][15] Görlich and Ribbeck also showed that molecular transport through nuclear pore complexes may be facilitated by hydrophobic interactions.[15]

As a postdoctoral researcher at the European Molecular Biology Laboratory, Ribbeck studied proteins involved in the organization of the mitotic spindle, a dynamic bundle consisting of proteins and molecules that aids in chromosome segregation during cell division.[16] Her research contributed to the discovery of a novel protein (NuSAP) that plays a crucial role in mitotic spindle organization.[17]

In 2007, Ribbeck's research returned to hydrogels, with a specific focus on mucus, i.e., a large natural hydrogel that is closely related to the polymer network she and Görlich had proposed to exist within nuclear pore complexes.[15][18][19] Her work has elucidated the role of mucins, a primary component of mucus, in human health.[2] Ribbeck is known for her pioneering work in this field, which has shown that mucus plays an active role in protecting against harmful pathogens,[20][21] including fungi, bacteria, and viruses. Specifically, her research has shown that mucins and their associated sugar chains (glycans) can "tame" pathogens by inhibiting virulence traits such as biofilm formation, cell adhesion, and toxin secretion.[22][23][24][25]

She has shown that mucins prevent bacteria such as Pseudomonas aeruginosa and Streptococcus mutans, the bacteria that cause tooth decay, from forming biofilms, which make them hard to eradicate.[26][27] Ribbeck demonstrated that mucin glycans can reduce the virulence of pathogens such as Pseudomonas aeruginosa,[22][23][28] a bacterium that can cause illness in individuals with cystic fibrosis or compromised immune systems, by inhibiting the cell-cell communication, toxin secretion, and biofilm formation ability of these bacteria.

Ribbeck's work has also demonstrated the role of mucus in protecting against fungal infections. Her studies have shown that mucins and specific mucin glycans induce a morphological change, accompanied by a reduction in biofilm formation and cell adhesion, in Candida albicans, a fungal pathogen that causes a variety of diseases in humans.[24][29] Her work has also shown that mucins found in multiple types of mucus, including human spit, can prevent fungal pathogens from causing disease in healthy humans.[24][27][30]

Ribbeck identified a correlation between the properties of mucus in the cervix in pregnant women and the likelihood of preterm birth[31] and has developed probes to test mucus permeability as a step towards diagnosing the risk for premature birth.[32]

Ribbeck has extensively investigated the biophysical properties of mucus and other hydrogels and the mechanisms by which some particles and molecules, including viruses such as SARS-CoV-2,[33] selectively pass through the barrier.[18][34][35][36] Ribbeck has also studied hydrogels produced by pathogens and has found that the extracellular matrix formed by the pathogenic bacterium Pseudomonas aeruginosa protects the bacterium against antibiotics.[37]

Ribbeck has investigated approaches for engineering mucus, with the aim of potentially influencing the population of bacteria in the human body.[38][39] In collaboration with others, Ribbeck demonstrated that synthetic mucins can block toxins produced by Vibrio cholerae, the bacteria that causes cholera.[25][40] She has also shown that purified foreign mucins can prevent viruses from infecting cells and suggested that they could be used to supplement the anti-viral activity of native mucins.[41]